Stem Cell Therapy Market In Asia-Pacific To 2018 - Commercialization Supported By Favorable Government Policies, Strong Pipeline And Increased Licensing Activity


GBI Research, the leading business intelligence provider, has released its latest research Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

    
 
GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals JR-031 (2014) in Japan and FCB Pharmicells Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. 

Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

 
Scope
  • Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore
  • In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. 
  • Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. 
  • Key drivers and restraints that have a significant impact on the market.
  • Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost
  • Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.
Reasons to buy
  • Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth 
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
  • Develop key strategic initiatives by studying the key strategies of top competitors
  • Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety
Browse : Browse Report : Stem Cell Therapy Market 2018

Table of Contents
 
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10


2 Stem Cell Therapy Market in Asia-Pacific to 2018 - Introduction 13

3 Stem Cell Therapy Market in Asia-Pacific to 2018 - Overview 14

3.1 Introduction 14
3.2 Market Characterization and Forecasts - Overview 15
3.2.1 Revenue Forecasts 15
3.2.2 Cost of Therapy 16
3.2.3 Allogeneic and Autologous Share 17
3.2.4 Stem Cell Therapy Patient Pool 18
3.3 Drivers and Barriers 19
3.3.1 Drivers 20
3.3.2 Barriers 20
4 Stem Cell Therapy Market in Asia-Pacific to 2018 - India 21
4.1 Introduction 21
4.2 Regulatory Landscape 21
4.3 Market Characterization and Forecasts - Overview 22
4.3.1 Revenue Forecasts 22
4.3.2 Cost of Therapy 23
4.3.3 Stem Cell Patient Pool 23
4.4 CABG Market Characterization and Forecasts 24
4.4.1 Introduction 24
4.4.2 Revenue Forecasts 24
4.4.3 Cost of Therapy 25
4.4.4 Stem Cell Patient Pool 26
4.5 Type 2 DM Market Characterization and Forecasts 27
4.5.1 Introduction 27
4.5.2 Revenue Forecasts 28
4.5.3 Cost of Therapy 29
4.5.4 Stem Cell Patient Pool 30
4.6 LSCT Market Characterization and Forecasts 31
4.6.1 Introduction 31
4.6.2 Revenue Forecasts 31
4.6.3 Cost of Therapy 32
4.6.4 Stem Cell Patient Pool 33

5 Stem Cell Therapy Market in Asia-Pacific to 2018 - China 34
5.1 Introduction 34
5.2 Regulatory Landscape 34
5.3 Market Characterization and Forecasts - Overview 35
5.3.1 Type 1 DM Market Characterization and Forecasts 35

6 Stem Cell Therapy Market in Asia-Pacific to 2018 - Japan 39
6.1 Introduction 39
6.2 Regulatory Landscape 39
6.3 Steroid Refractory aGvHD Market Characterization and Forecasts 41
6.3.1 Overview 41
6.3.2 Revenue Forecasts 42
6.3.3 Cost of Therapy 43
6.3.4 Stem Cell Patient Pool 44

7 Stem Cell Therapy Market in Asia-Pacific to 2018 - Singapore 45
7.1 Introduction 45
7.2 Regulatory Landscape 45
7.2.1 Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002) 46
7.2.2 Human Tissue Research (November 2002) 47
7.2.3 Research Involving Human Subjects (November 2004) 48
7.2.4 Genetic Testing and Genetic Research (November 2005) 49
7.2.5 Personal Information in Biomedical Research (May 2007) 50
7.2.6 Donation of Human Eggs for Research (November 2008) 50
7.2.7 Human-Animal Combinations in Stem Cell Research (September 2010) 50

8 Stem Cell Therapy Market in Asia-Pacific to 2018 - South Korea 51
8.1 Introduction 51
8.2 Regulatory Landscape 51
8.3 Market Characterization and Forecasts - Overview 53
8.3.1 Revenue Forecasts 53
8.3.2 Cost of Therapy 55
8.3.3 Stem Cell Patient Pool 56
8.4 Cupistem Market Characterization and Forecasts 57
8.4.1 Overview 57
8.4.2 Revenue Forecasts 58
8.4.3 Cost of Therapy 59
8.4.4 Stem Cell Patient Pool 60
8.5 HCG-AMI Market Characterization and Forecasts 61
8.5.1 Overview 61
8.5.2 Revenue Forecasts 62
8.5.3 Cost of Therapy 63
8.5.4 Stem Cell Patient Pool 64
8.6 Cartistem Market Characterization and Forecasts 65
8.6.1 Overview 65
8.6.2 Revenue Forecasts 66
8.6.3 Cost of Therapy 67
8.6.4 Stem Cell Patient Pool 68
8.7 CCG Market Characterization and Forecasts 69
8.7.1 Overview 69
8.7.2 Revenue Forecasts 69
8.7.3 Cost of Therapy 70
8.7.4 Stem Cell Patient Pool 71

9 Stem Cell Therapy Market in Asia-Pacific to 2018 - Pipeline Analysis 72
9.1 Pipeline Analysis by Phase 72
9.2 Pipeline Analysis by Sponsors/Collaborators 73
9.3 Pipeline Analysis by Country 74
9.3.1 India Stem Cell R&D Pipeline 75
9.3.2 China Stem Cell R&D Pipeline 77
9.3.3 Japan Stem Cell R&D Pipeline 81
9.3.4 Singapore Stem Cell R&D Pipeline 85
9.3.5 South Korea Stem Cell R&D Pipeline 86
9.3.6 Product Profiles of Promising Molecules 88
9.3.7 Product Profiles of Marketed Products 89

10 Stem Cell Therapy Market in Asia-Pacific to 2018 - Competitive Landscape 91
10.1 Stempeutics Research 91
10.1.1 Overview 91
10.1.2 Product Pipeline 92
10.2 Reliance Life Sciences 93
10.2.1 Overview 93
10.2.2 Product Pipeline 93
10.3 International Stem Cell Services 94
10.3.1 Overview 94
10.3.2 Product Pipeline 94
10.4 Shenzhen Beike Biotechnology 95
10.4.1 Overview 95
10.4.2 Product Pipeline 95
10.5 JCR Pharmaceuticals 96
10.5.1 Overview 96
10.5.2 Product Pipeline 96
10.6 ES Cells International (Subsidiary of BioTime, Inc) 97
10.6.1 Overview 97
10.6.2 Product Pipeline 97
10.7 Stem Cell Technologies i 98
10.7.1 Overview 98
10.7.2 Product Pipeline 98
10.8 Pharmicell 99
10.8.1 Overview 99
10.8.2 Product Pipeline 99
10.9 Medipost 100
10.9.1 Overview 100
10.9.2 Product Pipeline 100

11 Stem Cell Therapy Market in Asia-Pacific to 2018 - Strategic Consolidations 101
11.1 Overview 101
11.2 M&A Deals 102
11.2.1 RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m - October 28, 2011 102
11.2.2 BioTime Acquired ES Cell International - May 3, 2010 102
11.2.3 BCCL Acquires Stake in Life Cell - May 1, 2007 102
11.3 Licensing Deals 102
11.3.1 RNL BIO Forms Joint Venture to Develop Stem Cell Therapy - September 29, 2011 102
11.3.2 Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR - January 4, 2011 102
11.3.3 Cipla Enters into Co-Marketing Agreement with Stempeutics - April 27, 2010 102
11.3.4 Teijin Enters into Licensing Agreement with SanBio - March 2, 2010 102
11.3.5 Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma - September 9, 2009 103
11.3.6 Merck Signs a Licensing Agreement with Japan Tobacco - September 25, 2008 103
11.3.7 ES Cell Enters into Licensing Agreement with ITI Life Sciences - January 31, 2007 103
11.4 Co-Development Deals 103
11.4.1 JCR Pharma Enters into Co-Development Agreement with MediPal - September 13, 2011 103
11.4.2 Athersys Enters into Co-Development Agreement with Pfizer - December 21, 2009 103
11.4.3 Genzyme Enters into Agreement with Osiris Therapeutics - November 4, 2008 104
11.4.4 JCR Pharma Enters into Co-Development Agreement with Mochida Pharma - December 21, 2007 104

12 Stem Cell Therapy Market in Asia-Pacific to 2018 - Appendix 105
12.1 Market Definitions 105
12.2 Abbreviations 105
12.3 Bibliography 107
12.4 Research Methodology 108
12.4.1 Coverage 108
12.4.2 Secondary Research 108
12.4.3 Primary Research 109
12.5 Therapeutic Landscape 109
12.5.2 Market Size by Geography 111
12.6 Geographical Landscape 112
12.7 Pipeline Analysis 112
12.8 Competitive Landscape 112
12.8.1 Expert Panel Validation 112
12.9 Contact Us 112
12.10 Disclaimer 112
.

0 comments:

Post a Comment

Note: only a member of this blog may post a comment.

Search This Blog

Archives

Business Research Industry. Powered by Blogger.